Cargando…

Targeting Ferroptosis Pathway to Combat Therapy Resistance and Metastasis of Cancer

Ferroptosis is an iron-dependent regulated form of cell death caused by excessive lipid peroxidation. This form of cell death differed from known forms of cell death in morphological and biochemical features such as apoptosis, necrosis, and autophagy. Cancer cells require higher levels of iron to su...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xuan, Zhang, Yiqian, Wu, Xuyi, Xu, Fuyan, Ma, Hongbo, Wu, Mengling, Xia, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280276/
https://www.ncbi.nlm.nih.gov/pubmed/35847022
http://dx.doi.org/10.3389/fphar.2022.909821
_version_ 1784746603329880064
author Liu, Xuan
Zhang, Yiqian
Wu, Xuyi
Xu, Fuyan
Ma, Hongbo
Wu, Mengling
Xia, Yong
author_facet Liu, Xuan
Zhang, Yiqian
Wu, Xuyi
Xu, Fuyan
Ma, Hongbo
Wu, Mengling
Xia, Yong
author_sort Liu, Xuan
collection PubMed
description Ferroptosis is an iron-dependent regulated form of cell death caused by excessive lipid peroxidation. This form of cell death differed from known forms of cell death in morphological and biochemical features such as apoptosis, necrosis, and autophagy. Cancer cells require higher levels of iron to survive, which makes them highly susceptible to ferroptosis. Therefore, it was found to be closely related to the progression, treatment response, and metastasis of various cancer types. Numerous studies have found that the ferroptosis pathway is closely related to drug resistance and metastasis of cancer. Some cancer cells reduce their susceptibility to ferroptosis by downregulating the ferroptosis pathway, resulting in resistance to anticancer therapy. Induction of ferroptosis restores the sensitivity of drug-resistant cancer cells to standard treatments. Cancer cells that are resistant to conventional therapies or have a high propensity to metastasize might be particularly susceptible to ferroptosis. Some biological processes and cellular components, such as epithelial–mesenchymal transition (EMT) and noncoding RNAs, can influence cancer metastasis by regulating ferroptosis. Therefore, targeting ferroptosis may help suppress cancer metastasis. Those progresses revealed the importance of ferroptosis in cancer, In order to provide the detailed molecular mechanisms of ferroptosis in regulating therapy resistance and metastasis and strategies to overcome these barriers are not fully understood, we described the key molecular mechanisms of ferroptosis and its interaction with signaling pathways related to therapy resistance and metastasis. Furthermore, we summarized strategies for reversing resistance to targeted therapy, chemotherapy, radiotherapy, and immunotherapy and inhibiting cancer metastasis by modulating ferroptosis. Understanding the comprehensive regulatory mechanisms and signaling pathways of ferroptosis in cancer can provide new insights to enhance the efficacy of anticancer drugs, overcome drug resistance, and inhibit cancer metastasis.
format Online
Article
Text
id pubmed-9280276
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92802762022-07-15 Targeting Ferroptosis Pathway to Combat Therapy Resistance and Metastasis of Cancer Liu, Xuan Zhang, Yiqian Wu, Xuyi Xu, Fuyan Ma, Hongbo Wu, Mengling Xia, Yong Front Pharmacol Pharmacology Ferroptosis is an iron-dependent regulated form of cell death caused by excessive lipid peroxidation. This form of cell death differed from known forms of cell death in morphological and biochemical features such as apoptosis, necrosis, and autophagy. Cancer cells require higher levels of iron to survive, which makes them highly susceptible to ferroptosis. Therefore, it was found to be closely related to the progression, treatment response, and metastasis of various cancer types. Numerous studies have found that the ferroptosis pathway is closely related to drug resistance and metastasis of cancer. Some cancer cells reduce their susceptibility to ferroptosis by downregulating the ferroptosis pathway, resulting in resistance to anticancer therapy. Induction of ferroptosis restores the sensitivity of drug-resistant cancer cells to standard treatments. Cancer cells that are resistant to conventional therapies or have a high propensity to metastasize might be particularly susceptible to ferroptosis. Some biological processes and cellular components, such as epithelial–mesenchymal transition (EMT) and noncoding RNAs, can influence cancer metastasis by regulating ferroptosis. Therefore, targeting ferroptosis may help suppress cancer metastasis. Those progresses revealed the importance of ferroptosis in cancer, In order to provide the detailed molecular mechanisms of ferroptosis in regulating therapy resistance and metastasis and strategies to overcome these barriers are not fully understood, we described the key molecular mechanisms of ferroptosis and its interaction with signaling pathways related to therapy resistance and metastasis. Furthermore, we summarized strategies for reversing resistance to targeted therapy, chemotherapy, radiotherapy, and immunotherapy and inhibiting cancer metastasis by modulating ferroptosis. Understanding the comprehensive regulatory mechanisms and signaling pathways of ferroptosis in cancer can provide new insights to enhance the efficacy of anticancer drugs, overcome drug resistance, and inhibit cancer metastasis. Frontiers Media S.A. 2022-06-30 /pmc/articles/PMC9280276/ /pubmed/35847022 http://dx.doi.org/10.3389/fphar.2022.909821 Text en Copyright © 2022 Liu, Zhang, Wu, Xu, Ma, Wu and Xia. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Liu, Xuan
Zhang, Yiqian
Wu, Xuyi
Xu, Fuyan
Ma, Hongbo
Wu, Mengling
Xia, Yong
Targeting Ferroptosis Pathway to Combat Therapy Resistance and Metastasis of Cancer
title Targeting Ferroptosis Pathway to Combat Therapy Resistance and Metastasis of Cancer
title_full Targeting Ferroptosis Pathway to Combat Therapy Resistance and Metastasis of Cancer
title_fullStr Targeting Ferroptosis Pathway to Combat Therapy Resistance and Metastasis of Cancer
title_full_unstemmed Targeting Ferroptosis Pathway to Combat Therapy Resistance and Metastasis of Cancer
title_short Targeting Ferroptosis Pathway to Combat Therapy Resistance and Metastasis of Cancer
title_sort targeting ferroptosis pathway to combat therapy resistance and metastasis of cancer
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280276/
https://www.ncbi.nlm.nih.gov/pubmed/35847022
http://dx.doi.org/10.3389/fphar.2022.909821
work_keys_str_mv AT liuxuan targetingferroptosispathwaytocombattherapyresistanceandmetastasisofcancer
AT zhangyiqian targetingferroptosispathwaytocombattherapyresistanceandmetastasisofcancer
AT wuxuyi targetingferroptosispathwaytocombattherapyresistanceandmetastasisofcancer
AT xufuyan targetingferroptosispathwaytocombattherapyresistanceandmetastasisofcancer
AT mahongbo targetingferroptosispathwaytocombattherapyresistanceandmetastasisofcancer
AT wumengling targetingferroptosispathwaytocombattherapyresistanceandmetastasisofcancer
AT xiayong targetingferroptosispathwaytocombattherapyresistanceandmetastasisofcancer